Product Description
CPG 10101 (ACTILON) is a novel potent and selective unmethylated cytidine-phosphate-guanosine (CpG)-containing oligodeoxynucleotide agonist of Toll-like receptor 9 (TLR9) being developed for the treatment of chronic infections such as HCV.
Mechanisms of Action: TLR9 Agonist
Novel Mechanism: Yes
Modality: Unknown
Route of Administration: Oral, Subcutaneous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Pfizer
Company Location: Eastern America
Company Founding Year: 1849
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Hepatitis C, Chronic|Hepatitis A
Phase 1: Hepatitis A|Hepatitis C, Chronic
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT00142103 |
B1211001 | P1 |
Completed |
Hepatitis C, Chronic|Hepatitis A |
2007-02-01 |
2019-03-21 |
||
NCT00277238 |
B1211002 | P2 |
Completed |
Hepatitis A|Hepatitis C, Chronic |
2007-07-01 |
2019-03-21 |
Treatments |